Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Financings Neutral

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles

By The Northwire Desk — AI Analysis May 29, 2026 · 07:30 APS · 2.28 APTOSE BIOSCIENCES INC.
Executive Summary
  • Transaction Status: The Plan of Arrangement with Hanmi Pharmaceutical Co. Ltd. has been delayed from May 2026 to June 2026 due to pending Korean regulatory approvals.
  • Closing Terms: Upon completion, Hanmi Purchasers will acquire all outstanding common shares not currently owned by them for C$2.41 in cash per share (a 28% premium over the 30-day VWAP of C$1.88).
  • Financing Update: Aptose received an additional US$2.0 million advance from Hanmi under a US$11.9 million amended facility agreement. The final advance is expected shortly to complete the total facility value.
  • Operational Continuity: Proceeds support uninterrupted continuance of the TUSCANY clinical trial (tuspetinib + venetoclax + azacitidine) for frontline treatment of newly diagnosed AML.
  • Confidence Level: Parties do not anticipate that regulatory delays will prevent completion of the transaction.
Material Impact
  • Deal Certainty: The delay introduces a short-term timeline extension but does not alter the fundamental value proposition (C$2.41 cash exit). Shareholder and court approvals were already secured in March 2026, reducing structural risk.
  • Liquidity Risk Mitigation: The US$2.0 million advance is critical given Q1 2026 net losses of $7.6 million and a cash position of only $4.1 million as of March 31, 2026. This funding prevents immediate bankruptcy risk prior to closing.
  • Market Sentiment: The stock price ($2.28) is trading slightly below the offer price ($2.41), indicating an arbitrage spread that may widen slightly due to the delay but remains tight enough to suggest high deal confidence.
  • Routine Nature: This update follows previous delays announced in April 2026 (targeting May). The financing advance was part of the previously disclosed facility agreement terms, making this execution rather than a new strategic pivot.
APS · Price
Company Overview
  • Company: Aptose Biosciences Inc., a clinical-stage biopharmaceutical company focused on oncology.
  • Flagship Project: Tuspetinib (TUS), an oral pan-FGFR inhibitor.
  • Clinical Program: TUSCANY Phase 1/2 trial evaluating tuspetinib in combination with venetoclax and azacitidine for frontline treatment of newly diagnosed AML patients ineligible for intensive chemotherapy.
  • Data Highlights: Recent data (ASH 2025, EHA 2026) shows high response rates (90% overall CR/CRh; 100% at 80mg and 120mg doses) with favorable safety profiles across diverse mutational subtypes including TP53-mutated disease.
  • Secondary Program: Luxeptinib program costs decreased as the trial is being wound down; license rights returned to CGI Invites Co., Ltd.
Read the original news release →

More from APTOSE BIOSCIENCES INC.

Jun 30, 2026 · 19:32

Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

M&A / Property Jun 15, 2026 · 07:30

Clinical data validates tuspetinib's AML potential, but acquisition hinges on delayed Korean regulatory approval.

Other May 13, 2026 · 17:00

Hanmi Acquisition Delayed to May 2026 as Aptose Burns Cash Faster Than Expected

Earnings Apr 30, 2026 · 07:30

Hanmi Acquisition Closing Delayed to May as Korean Regulatory Review Continues

M&A / Property Mar 31, 2026 · 17:22

Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy

Earnings Mar 23, 2026 · 17:17

Aptose Bio gets Glass, Lewis support for takeover

M&A / Property